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Abstract. Background & aims: Pathogenesis of gastric cancer is driven by an accumulation of genetic changes that to a large
extent occur at the chromosomal level. In order to investigate the patterns of chromosomal aberrations in gastric carcinomas, we
performed genome-wide microarray based comparative genomic hybridisation (microarray CGH). With this recently developed
technique chromosomal aberrations can be studied with high resolution and sensitivity.
Methods: Array CGH was applied to a series of 35 gastric adenocarcinomas using a genome-wide scanning array with 2275
BAC and P1 clones spotted in triplicate. Each clone contains at least one STS for linkage to the sequence of the human genome.
These arrays provide an average resolution of 1.4 Mb across the genome. DNA copy number changes were correlated with
clinicopathological tumour characteristics as well as survival.
Results: All thirty-five cancers showed chromosomal aberrations and 16 of the 35 tumours showed one or more amplifica-
tions. The most frequent aberrations are gains of 8q24.2, 8q24.1, 20q13.12, 20q13.2, 7p11.2, 1q32.3, 8p23.1–p23.3, losses of
5q14.1, 18q22.1, 19p13.12–p13.3, 9p21.3–p24.3, 17p13.1–p13.3, 13q31.1, 16q22.1, 21q21.3, and amplifications of 7q21–q22,
and 12q14.1–q21.1. These aberrations were correlated to clinicopathological characteristics and survival. Gain of 1q32.3 was sig-
nificantly correlated with lymph node status (p = 0.007). Tumours with loss of 18q22.1, as well as tumours with amplifications
were associated with poor survival (p = 0.02, both).
Conclusions: Microarray CGH has revealed several chromosomal regions that have not been described before in gastric cancer
at this frequency and resolution, such as amplification of at 7q21–q22 and 12q14.1–q21.1, as well gains at 1q32.3, 7p11.2, and
losses at 13q13.1. Interestingly, gain of 1q32.3 and loss of 18q22.1 are associated with a bad prognosis indicating that these
regions could harbour gene(s) that may determine aggressive tumour behaviour and poor clinical outcome.
Keywords: Microarray comparative genomic hybridisation, gastric cancer, survival, lymph node, 1q gain, 18q loss, amplification,
7q21–22, 12q
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1. Introduction
Gastric adenocarcinoma is a common cause of can-
cer death, and it is the fourth most common cancer
worldwide [33]. In The Netherlands it ranks fifth, with
approximately 2200 new cases annually [45]. Heli-
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cobacter pylori (H. pylori) is a major etiologic factor
probably interacting with dietary factors, and possibly
Epstein Barr virus also plays a role in a subset of cases
[5,12,40]. In general, for an epithelial cell to trans-
form to a cancer cell, it must acquire capabilities of
autonomous proliferation, destruction and remodelling
of basal membrane and intercellular matrix, motility,
stroma induction and angiogenesis [10]. Ultimately it
must escape from the immune system. Tumour cells
acquire these features in part by an accumulation of
genomic changes. Thus, pathogenesis of gastric cancer
is driven by an accumulation of genetic changes, and
these occur to a large extent at the chromosomal level.
Despite the high incidence, knowledge of the genetic
events leading to gastric adenocarcinomas is still lim-
ited.
Analysis of chromosomal imbalances by compar-
ative genomic hybridisation (CGH) has greatly con-
tributed to the current knowledge of genomic alter-
ations associated with gastric cancer and number of
chromosomal regions with frequent gains or losses
have been identified [12,22–24,44,49]. However, the
information obtained is limited to a resolution of
approximately 3–10 Mb. Furthermore, chromosome
CGH data are less suitable for quantitative analyses
like genomic tumour profiling. Microarray based CGH
overcomes these limitations to a large extent. It has a
much higher resolution and produces quantitative data.
Indeed we could previously demonstrate superior sen-
sitivity and resolution of microarray based CGH in the
analysis of a region on chromosome 20q that is fre-
quently gained in gastric cancer [48]. In order to obtain
a detailed overview of the chromosomal gains, losses
and amplifications in gastric adenocarcinomas with a
higher resolution than has been possible so far, we ap-
plied this new technique.
Previously we demonstrated that unsupervised clus-
ter analysis of microarray CGH data in gastric cancer
yielded subgroups that differed with respect to survival
and risk of lymph node metastasis [47]. In the present
study we have investigated the occurrence of specific
chromosomal imbalances in gastric cancer, and their
correlation to clinicopathological characteristics.
2. Material and methods
2.1. Material
Thirty-five patients with primary gastric adenocar-
cinoma who had undergone (partial) gastrectomy, and
of which fresh frozen material was available, were in-
cluded in the study, as has been described previously
[47]. Twenty-six patients were male, and nine were fe-
male, with a mean age of 67.4 years (range 32–90).
Twenty-five carcinomas were of the intestinal type ac-
cording to the Laurèn classification [26], five were of
the diffuse type, and five showed a mixed histology
(components were not analysed separately). Tumours
with cohesive tumour cell proliferations were classified
as intestinal. In all these cases (remnants of) glan-
dular differentiation was present, and in most cases
intestinal metaplasia could be observed in the adjacent
mucosa. Tumours with a diffusely infiltrating prolifer-
ation of individual tumour cells, frequently with signet
cell features, were classified as diffuse type carcino-
mas. Occasionally in these tumours a relation with the
glandular layer of the gastric mucosa was observed.
Tumours that showed both cohesive parts and dif-
fusely infiltrating solitary tumour cells were classified
as mixed types. Eleven tumours were moderately dif-
ferentiated and 24 poorly differentiated. Two tumours
were stage I, 2 were stage II, 23 were stage III, and
8 were stage IV. Twelve patients were lymph node
negative and 23 lymph node positive. Follow-up data
were available in 33 of 35 (94%) of cases (mean 21.2
months; range 2–104).
DNA was isolated from snap-frozen tumour samples
taken from the gastrectomy specimens. The samples
were obtained from the archives of the Department
of Pathology of the VU University Medical Centre.
Only cases were included that had a tumour content of
>75% in the (sandwich) H&E stained sections taken
before and after the sections used for DNA isola-
tion. Normal human male genome DNA was isolated
from lymphocytes obtained from a blood bank. DNA
isolation was performed following the manufacturers
instructions (Qiamp Tissue Kit – QIAgen Inc., Valen-
cia, CA, USA), with some modifications as described
before [46].
2.2. Microarrays
Microarrays were produced as described previously
[41]. In short, DNA isolated from BAC clones was am-
plified using ligation-mediated PCR to generate rep-
resentations of these human BAC DNAs. The DNAs
were spotted on chromium coated microscope slides
using a custom built arrayer. Genome wide scanning
arrays were used as described before [1,34,41]. The
scanning array comprised DNA from 2275 BAC and
P1 clones spotted in triplicate, evenly spread across
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the whole genome at an average resolution of 1.4 Mb.
Chromosome X-clones (n = 61) were discarded from
further analysis since all tumour samples were hy-
bridised to male reference DNA, leaving 2214 clones
per array to be evaluated. Each clone contains at least
one STS for linkage to the sequence of the human
genome.
2.3. Comparative hybridisation
Test and reference genomic DNA (300–500 ng of
each) were labelled by random priming (BioPrime
DNA labelling system, Gibco BRL) in a 100 µl reac-
tion with Cy3 dCTP (Amersham Pharmacia Biotech)
and fluorescein dCTP (DuPont NEN NEL424), respec-
tively, as described previously [41]. Non-incorporated
nucleotides were removed using a Sephadex G-50 spin
column. Labelled DNA (∼600 ng of input DNA) was
mixed with Cot-1 DNA (80–100 µg; Gibco BRL) and
ethanol precipitated. The precipitated DNA was dis-
solved in hybridisation mix (50 µl) to achieve a final
composition of 50% formamide, 10% dextran sulfate,
2×SSC, 4% SDS and 500 µg yeast tRNA. The hybridi-
sation solution was heated to 70◦C for 10–15 minutes
to denature the DNA, and subsequently continued in-
cubation at 37◦C for approximately 60 minutes to
allow blocking of the repetitive sequences. A ring of
rubber cement closely around the array was applied
to form a well, into which we added 50 µl of slide
blocking solution containing 500 µg salmon sperm
DNA. After a 30 min incubation at room temperature,
approximately three-quarters of the blocking solution
was removed, and the denatured and re-annealed hy-
bridisation mixture was added. The arrays were placed
on a slowly rocking table (∼1 rpm) at 37◦C to allow
hybridisation to occur over 48–72 hours. After hybridi-
sation, slides were washed once in 50% formamide,
2 × SSC, pH 7, at 45◦C for 15 minutes, and once in
PN buffer (PN: 0.1 M sodium phosphate, 0.1% nonidet
P40, pH 8) at room temperature for 15 minutes. Ex-
cess liquid was drained from the slides and the array
was mounted in an antifade solution containing DAPI
(1 µg/ml) to counterstain the DNA targets.
2.4. Image acquisition
Image acquisition and analysis, and data extraction
were performed as described previously [34]. In short,
DAPI, Cy3, and fluorescein images were captured us-
ing a CCD based imaging system and stored as TIF
files in a 1024× 1024 resolution.
2.5. Data analysis and statistical analysis
Image analysis and feature extraction were done
with dedicated software: UCSF SPOT software [17]
(www.jainlab.org) was used to automatically segment
the spots based on the DAPI images, perform lo-
cal background correction and to calculate various
measurement parameters, including log2 ratios of the
total integrated Cy3 and Cy5 intensities for each spot.
A second custom program, SPROC (www.jainlab.org),
was used to associate clone identities and a mapping
information file with each spot so that the data could
be plotted relative to the position of the BACs on the
September 2000 freeze of the draft human genome
sequence (http://genome.ucsc.edu/). The precise loca-
tion of the amplicons and common region of overlaps
of gains and losses was confirmed by comparing to
the April 2002 freeze draft human genome sequence
(http://genome.ucsc.edu/). The SPROC output consists
of log2 transformed averaged fluorescence ratios of the
triplicate spots for each clone, standard deviations of
the triplicates and plotting position for each clone on
the array. Ratios of clones for which only one of the
triplicates remained after SPROC analysis were ex-
cluded from further analysis.
Chromosomal aberrations were classified as a gain
when the normalized log2 transformed fluorescence ra-
tio was higher than 0.2; as a loss when this ratio was
below −0.2. Neighbouring clones with a similar log2
transformed fluorescence ratio exceeding these borders
were regarded to belong to the same chromosomal gain
or loss, respectively. Events were considered real when
at least 4 neighbouring clones had log2 ratios below or
above the thresholds. Steep copy number changes with
the graph showing a peak rather than a plateau, with a
minimal normalized log2 transformed fluorescence ra-
tio of 1.0 or larger, were classified as amplifications.
Multiple gains, losses and amplifications were counted
as separate events.
2.6. Statistical analyses
For comparing means of continuous variables be-
tween two or more groups, Student’s t-test and one-
way analysis of variance (ANOVA) were used, re-
spectively. For testing significance of differences in
distribution of categorical variables, cross tables were
analysed with the two-sided Fisher Exact’s test and
Pearson’s test, depending on the number of cate-
gories. Univariate survival analysis was carried out by
Kaplan–Meier survival analysis and log-rank testing.
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P -values < 0.05 were considered significant, unless
otherwise specified. All statistical analyses were car-
ried out with SPSS software version 10 (SPSS Inc.,
Chicago, IL, USA).
3. Results
All thirty-five cancers showed chromosomal aber-
rations. The mean number of chromosomal events
(gains, losses, and amplifications) per case was 16.0
(range 3–53), with on average 7.9 gains (range 1–
28), 7.1 losses (range 0–23), and 1.0 amplification
(range 0–4). The most frequent aberrations are gains
of 8q24.2, 8q24.1, 20q13.12, 20q13.2, 7p11.2, 1q32.3,
8p23.1–p23.3, losses of 5q14.1, 18q22.1, 19p13.12–
p13.3, 9p21.3–p24.3, 17p13.1–p13.3, 13q31.1,
16q22.1, 21q21.3 (Table 1), and amplifications of
7q21.2–q22.3 and 12q14.1–q21.1 (Table 2). Exam-
ples of array CGH data of a few of these frequent
aberrations are shown in Fig. 1. An overview of all
chromosomal aberrations is displayed in Fig. 2. The to-
tal number of chromosomal aberrations (‘events’) was
significantly correlated to the number of amplifications
(r = 0.7, p < 0.0001).
All amplifications are summarized in Table 2. The
most frequent amplification was found at the long arm
of chromosome 7 (7/35 = 20%). In this region, three
Table 1
Most frequent common regions of overlap detected by microarray
comparative genomic hybridisation in 35 gastric adenocarcinomas,
together with candidate genes
Chromosomal
aberration
Number of
tumours
Candidate genes
1q32.3+ 10 (29%) NEK2
7p11.2+ 11 (31%) EGFR
8p23.1–23.3+ 10 (29%) GATA4; MASL1
8q24.1+ 19 (54%) ?
8q24.2+ 23 (66%) C-Myc
20q13.12+ 19 (54%) ?
20q13.2+ 18 (51%) CYP24; ZNF217
5q14.1− 14 (40%) MSH3
9p21.3–24.3− 10 (29%) INF
13q31.1− 9 (26%) ?
16q22.1− 9 (26%) CDH 1 (=E-Cadherin),
CDH3, CDH5, CDH16
17p13.1–13.3− 10 (29%) P53
18q22.1− 13 (37%) CDH 7 and CDH 19
19p13.12–13.3− 11 (31%) ?
21q21.3− 8 (23%) ?
Table 2
Genomic amplifications and candidate genes detected by microarray
comparative genomic hybridisation in 35 gastric adenocarcinomas,
together with candidate genes
Region of
amplification
Tumor Amplicon
size
Candidate
genes
1q21.1–q21.3 #5 5.3 Mb Phosphatidylinositol-
4-kinase, catalytic, β
(PIK4CB)
1q24.1–24.3 #8 6.0 Mb Flavin-containing
monooxygenase 1, 2,
3 and 4 (FMO1,
FMO2, FMO3,
FMO4) Myoc
3q26.1–q26.31 #8 10.2 Mb ?
4p11–q13.2 #12 12.0 PDGFRA
7p22.3–p21.3 #12 7.0 Mb ?
7p11.2 #10 0.56 Mb EGFR
7q21.2–q22.3 #6 3.7 Mb CDK6
#1 12.9 Mb MDR1
#10 16.4 Mb GNG11
#2 13.2 Mb
#7 22.3 Mb
#3 32.2 Mb
7q22.2–q31.1 #7 4.4 Mb PRKAR2B
7q22.2–q22.3 #2 2.8 Mb
7q31.1–q32.1 #11 18.1 Mb C-met; TFEC
#2 14.8 Mb
8p23.3–p23.2 #9 6.3 Mb GNB2L1
8p23.1 #14 3.4 Mb Cathepsin B
#9 2.9 Mb GATA-4
farnesyl-diphosphate
farnesyltransferase
(FDFT1)
8q24.13–q24.21 #10 6.3 Mb C-myc
10q22.1 #3 5.1 Mb ?
11p11.2–p12 #2 7.0 Mb diacylglycerol kinase
(DGKZ)
MDK
DDB2
novel death domain
(MADD)
PTPRJ
11q13.3–q14.1 #2 18.8 Mb Cyclin D1
peak of 4.6 Mb FGF3, 4, and 19
EMS1
12p12 #14 4.5 Mb K-ras
#15
12q14.1–q21.1 #4 7.7 Mb MDM2
#6 7.7 Mb interferon gamma
(IFNG)
#7 13.5 Mb MDM1
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Table 2
(Continued)
Region of
amplification
Tumor Amplicon
size
Candidate
genes
IL22
protein tyrosine
phosphatase, receptor
type, B (PTPRB)
13q13.1–q13.3 #1 5.6 Mb Cyclin A1
17q21.1–q21.3 #16 5.4 Mb Her2/neu
BRCA1
Topoisomerase II
19q12–q13.1 #5 4.2 Mb Cyclin E1
20p11.2 #8 1.5 Mb ?
20q13.11–q13.12 #13 1.9 Mb ?
20q13.2 #8 1.5 Mb CYP24
#12 15.0 Mb ZNF217
separate amplifications could be identified; 7q21.1–
q22.3, 7q22.2–q31.1, and 7q31.1–q32.1 (Fig. 3). The
second most frequent amplification, occurring in 3
tumours (3/35 = 9%), was found at chromosome
12q14.1–q21.1 in. Other amplifications occurred in
lower frequencies.
Array CGH data (all events in Table 1) were corre-
lated to lymph node status (negative or positive), histo-
logical type (intestinal, diffuse, mixed), differentiation
grade (moderate or poor), tumour stage (T1+T2 versus
T3 + T4), gender (male or female), and age (Table 3).
Of the individual gains and losses, gain of 1q32.3
was significantly correlated with lymph node status
(p = 0.007); all ten tumours harbouring gain of this
chromosomal locus were lymph node positive. Fur-
thermore, significant correlations were found between
loss of 17p13.1–p13.3 and histological type (p = 0.01;
4 of 5 diffuse type tumours and only 6 of 25 intesti-
nal type tumours showed loss of 17p), and loss of
18q22.1 with gender (p = 0.007; all 13 tumours show-
ing 18q22.1 loss were from male patients). None of
the other frequently occurring chromosomal common
regions of overlap were correlated with either lymph
node status, histological type, grade, stage, or gender.
Interestingly, loss of 18q22.1 and gain of 20q13.2 were
significantly correlated (p = 0.01). These events co-
occurred in 11 tumours and 13 tumours showed neither
18q22.1− nor 20q13.2+.
No correlations were found between any of the
above mentioned clinicopathological characteristics
and the presence or absence of amplifications.
In univariate analysis, patient survival was not cor-
related with the total number of gains, losses or events.
Fig. 1. Examples of microarray CGH results for three of the most
frequent common regions of overlap (boundaries are indicated by the
vertical lines). Clones are ordered by their position from pter (left)
to qter (right). The log2 fluorescence ratios of every clone in this
specific case are plotted as a line graphs. Multiple clear copy number
changes (gains, losses and amplifications) can be recognized.
However, presence of one or more amplifications was
significantly correlated with poor survival (log rank =
5.2, p = 0.02, hazard ratio 3.3 (95% confidence in-
terval 1.1–9.6)). When investigating individual events,
tumours with loss of 18q22.1 were associated with a
poorer survival (log rank = 5.9, p = 0.02, hazard ra-
tio 3.3 (95% confidence interval 1.2–10.0)). A similar
trend was seen for gain of 20q13.2, but this did not
reach statistical significance (log rank = 1.92, p =
0.17). None of the other individual events did corre-
late with survival, including gain of 1q32.3 (log rank =
2.28, p = 0.13) (Table 3).
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Fig. 2. Overview of chromosomal aberrations in 35 primary gastric carcinomas detected by microarray comparative genomic hybridisation. Each
bar represents a chromosomal aberration in an individual tumour. On the right side of the ideograms the gains (thin lines) and amplifications
(thick lines) are displayed, and on the left side the losses (thin lines).
4. Discussion
Chromosomal instability is a major mechanism of
genetic damage in gastric cancer as has been demon-
strated by classical CGH studies showing chromosome
abnormalities in almost all gastric tumours analysed
[9,23,44]. Events related to progression of gastric can-
cer include activating mutations, amplifications and
overexpression of various growth factors (e.g. epider-
mal growth factor (EGFR), platelet derived growth
factor (PDGFR), c-Met), signalling intermediates (e.g.
Ras, Protein Kinase C (PKC)), and cell cycle regula-
tory molecules (e.g. mouse double minute-2 (MDM2),
cyclin-dependent kinase-4 (CDK4), and CDK6, that
positively regulate proliferation and cell cycle progres-
sion. Amplifications of some of these oncogenes like
Cyclin D1 on 11q13, C-Met on 7q31 and HER2-neu/C-
erbB2 on 17q21–q22 have been described. A num-
ber of chromosomal losses, causing loss of tumour
suppressor function, have been identified in sporadic
gastric cancer, like p53 on 17p13, and E-cadherin
on16q22. However, the picture is yet far from com-
plete.
Although chromosome CGH has increased our pos-
sibilities to analyse the complete genome of primary
tumour samples in a single experiment, it has certain
limitations in resolution for chromosomal aberrations.
Array-based CGH, as used in this study, has overcome
this problem to a large extent [1,34]. The most frequent
amplification (6/35 = 17%) was located at 7q21–q22,
in the neighbourhood of this chromosomal region two
other amplified regions at the long arm of chromo-
some 7 were detected (Fig. 3). The common region of
overlap of the amplifications at 7q21–q22 is 3.7 Mb
in size. A putative candidate gene for driving the se-
lection of tumour cells harbouring this amplification
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Fig. 3. Detailed mapping of three regions of amplification on the long arm of chromosome 7. Seven tumours showed amplification at one or more
regions at 7q. The horizontal bars represent the length and position of the amplified regions. Thick bars represent the peak within the amplified
region. On the X-axeis the base position, chromosome band (image derived from http://genome.ucsc.edu/) and candidate genes are plotted.
Table 3
Correlations of DNA copy number changes with clinicopathological
characteristics and survival
Lymph node status Total p-value
Negative Positive
no 1q32.3+ 12 13 25 0.007
1q32.3+ – 10 10
Total 12 23 35
Histological type Total p-value
Intestinal Mixed Diffuse
no 17p13− 19 5 1 25 0.013
17p13− 6 4 10
Total 25 5 5 35
Sex Total p-value
Female Male
no 18q22.1− 9 13 22 0.007
18q22.1− 13 13
Total 9 26 35
Survival N Hazard Log p-value
ratio rank
no 18q22.1− Good 19 3.3 5.8 0.02
(1.2–10.0)
18q22.1− Poor 10
Total 29
No amplifications Good 16 3.3 5.2 0.02
(1.1–9.6)
Amplifications Poor 13
Total 29
at 7q21–q22 could be CDK6. The protein encoded by
this gene is a member of the CDK family. The D type
cyclins complex with CDK4 and CDK6 to govern pro-
gression through the G1 phase of the cell cycle and
later are involved with inactivating phosphorylation of
the Rb protein which results in release of Rb-associated
transcription factors that are needed for entry into S
phase. The activity of the CDKs is in part controlled
by inhibitors such as the INK4 family [32,39]. INK4a
(at 9p21.3) has been shown to act by competing with
CDK4 and CDK6 and functions as a tumour suppressor
in a variety of cancers. Inhibition of CDK6 prevents the
phosphorylation of Rb1 and maintains the Rb1–E2F
complex in its growth-suppressing state [19]. Amplifi-
cation of CDK6 has been detected in 6% of high-grade
astrocytic tumours [4], and in these tumours it was not
co-amplified with either EGFR or c-met, which map to
7p11.2 and 7q31.2, respectively. In the gastric carci-
nomas in the present study, amplification of the CDK6
region was found without co-amplification of other re-
gions at chromosome 7 in three tumours (#1, #3, #6).
In one tumour (#10), CDK6 was co-amplified with the
EGFR locus, and in 2 tumours (#2, #7) the chromo-
somal region of CDK6 was co-amplified with a small
region distal of CDK6 starting at 7q22.2 (Fig. 3). These
data suggest that the amplification of 7q21.2–q22.3
containing CDK6 may be a new specific amplicon in
gastric cancer.
One of the other amplified regions on 7q (in two tu-
mours) harbours the c-met gene, that has been found
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to be frequently overexpressed in gastric cancer (70%),
which was not caused by the activation of tpr, an up-
stream regulator of c-met [13]. Data on c-met protein
expression analysed by immunohistochemistry were
available for 13 cases of the present study [13]. Two
of these 13 cases showed amplification of the c-met
gene locus by array CGH, and interestingly both these
tumours showed overexpression of the c-met protein.
C-met amplification has been correlated with positive
lymph-node metastasis but not with other clinicopatho-
logical factors [29]. Also, in our set the two tumours
with c-met amplification are both lymph node positive.
Gains and amplifications of chromosome 7q have
been reported before in gastric cancer [6,24,25,30,43],
and c-met is in most cases suggested as the candidate
gene. However, in this study we showed that a region
proximal (7q21–q22) of c-met is amplified in a higher
percentage of gastric cancers analysed, suggesting that
another oncogene (e.g. CDK6) may be more important
in gastric carcinogenesis. These data show the advan-
tage of array CGH compared to chromosome CGH,
because of the higher resolution and the possibility to
position amplifications more precisely.
Amplification at chromosome 12q14.1–q21.1 is the
second most frequent amplification (3/35 = 9%).
A well-known candidate oncogene at this chromoso-
mal locus is MDM2 at 12q15. MDM2 is a multifunc-
tional protein that acts as a regulator of the tumour
suppressor p53. It binds to and abrogates the p53 func-
tion by either targeting p53 for degradation in the
cytoplasm by the proteosome, or by repressing p53-
mediated transcriptional activity in the nucleus [35].
The MDM2 gene enhances the tumourigenic potential
of cells in which it is overexpressed [20]. Furthermore,
MDM2 interacts physically and functionally with the
Rb protein and can inhibit its growth regulatory capac-
ity. So both Rb and p53 can be subjected to negative
regulation by the product of a single cellular pro-
tooncogene [50]. Recently, it has been shown that
MDM2 can interact with a large number of other cellu-
lar proteins besides p53 [8]. In our series of 35 gastric
carcinomas, however, there was no correlation between
amplification of the MDM2 and the p53 locus (1 tu-
mour with MDM2 amplification showed 17p loss, and
2 did not show 17p loss). The small number of 12q
amplifications, however, does not permit any final con-
clusions in this respect.
The amplification at 8p23.1 of the short arm of
chromosome 8 occurred in 2 tumours (6%). This re-
gion has been reported to be frequently amplified
in oesophageal (13.6%) and cardia adenocarcinomas
(12.5%) [27]. Candidate genes are GATA-4, a member
of a zinc finger transcription factor family, farnesyl-
diphosphate farnesyltransferase (FDFT1), and cathep-
sin B (CTSB). Both amplification and overexpression
of GATA-4, FDFT1 and CTSB have been reported
in oesophageal adenocarcinoma [15,27], indicating an
important role for these genes in the carcinogenesis
of gastrointestinal tumours. Furthermore, the MASL1
gene in this amplicon is reported as a candidate onco-
gene in malignant fibrous histiocytomas [37].
In many types of tumours, amplifications become
more prevalent with advanced tumour stage and are
rare in premalignant lesions [36]. This could mean
that low-level copy number increases (low-level gains)
of many genes on a chromosome arm is beneficial
to render an initial growth advantage to the cell,
whereas more localized high-level gains (or amplifica-
tions) could be important at later stages as a response
to selective environmental pressure. Frequently, the
presence of one or more amplifications is correlated
with clinicopathological characteristics that influence
survival, like tumour stage, grade, and lymph node
status. In the present study, the presence or absence
of amplifications was not correlated to any of the
clinicopathological characteristics, except for survival
(log rank = 5.2, p = 0.02, hazard ratio 3.3 (95% con-
fidence interval 1.1–9.6)) (Table 3).
In many types of tumours gain of 1q is associated
with a poor prognosis; e.g. with adverse overall sur-
vival and event-free survival in Ewing tumours [11],
with a higher relapse rate in breast cancer [51], and
with aggressive behaviour in ependymomas [3]. In the
present study, gastric cancer, gain of 1q32.3 was signif-
icantly correlated with lymph node status (p = 0.007);
all ten tumours harbouring gain of this chromosomal
locus were lymph node positive. Gain of 1q in gastric
cancers has been described as a frequent chromosomal
aberration by others [6,31,43], but not with this reso-
lution. In this regions the NEK2 gene, a member of the
Never In Mitosis A (NIMA) family of cell cycle regula-
tors, is one of the candidates. NEK2 is a protein kinase
that localizes to the centrosome. Overexpression of this
protein has two consequences; i.e. centrosome splitting
and the gradual disappearance of centrosomes, indicat-
ing that NEK2 could play a role in preparation of the
chromosomes for separation prior to the onset of mito-
sis. This suggests that NEK2 has a role in the cell cycle,
and could be involved in chromosomal instability [7].
Indeed, gain of the chromosomal locus of NEK2 at 1q
was significantly correlated with the total number of
events (p = 0.01).
M.M. Weiss et al. / Microarray CGH in gastric cancer 315
While 1q gain was correlated with lymph node sta-
tus, other chromosomal changes were correlated with
survival, indicating that yet other mechanisms than
lymph node metastasis determine patient outcome.
Loss of 18q22.1 was significantly correlated with poor
survival (log rank = 5.88, p = 0.015, hazard ratio 3.3
(95% confidence interval 1.2–10.0). Cadherins (CDH)
7 and 19 are located at this chromosomal band. The
cadherins are a family of cell surface molecules in-
volved in the structural and functional organization of
cells in various tissues. These proteins act as mediators
of selective cell–cell adhesion, which is a feature of
epithelium. Since disturbance of intercellular adhesion
is a prerequisite for invasion and metastasis of tu-
mour cells, cadherins are considered prime candidates
for tumour suppressor genes. Loss of E-cadherin (lo-
cated at 16q22.1) is a characteristic feature of diffuse
gastric cancer [28]. Loss of 16q22.1 is a frequent aber-
ration in this set of gastric carcinomas (9/35 = 26%).
Mutations occur at a very early non-invasive stage,
associating E-cadherin mutations with loss of growth
control. These mutations mostly occur in combination
with loss of heterozygosity (LOH) of the wild-type
allele, resulting in loss of E-cadherin mediated cell–
cell adhesion [2]. In this set of gastric tumours, loss
of 16q22.1 is not significantly correlated with histo-
logical type. However, there are only 5 (of 35) diffuse
type gastric carcinomas included in this study. Two of
which show loss of 16q22.1.
No correlation between loss of 18q22.1 and histo-
logical type was found in this study (of the 13 tumours
with losses of 18q22.1, 11 were of the intestinal, 1
was of the mixed and 1 was of the diffuse type).
LOH on chromosome 18q22–23 has been reported
to correlate with serosal invasion, haematogenous re-
currence and survival in gastric carcinomas [16]. In
colon cancer, loss of 18q12–21 is a strong indicator
for progression in colorectal carcinogenesis (signifi-
cant correlation with grade of dysplasia), as well as
survival [14,18]. Although the specific gene(s) on 18q
in both gastric and colorectal cancer have not yet
been identified, the DCC and Smad4 are candidates.
Expression of DCC in gastric and colon cancer is de-
creased, and in colon cancer this correlates with the
development of nodal metastasis [21]. Using mouse
models, it has been suggested that SMAD−/− ade-
nomas in the colon are larger and progress quicker
[42]. However, the chromosomal region involved in
colorectal and gastric carcinogenesis seems to be dif-
ferent but still close to each other (18q12–21 and
18q22.1, respectively). Taken into account the resolu-
tion of chromosome CGH, and even array CGH, it may
very well be possible that it is indeed the same chro-
mosomal region that harbours the candidate tumour
suppressor gene important in gastric and colorectal car-
cinogenesis. This is in line with the fact that in both
gastric and colorectal cancer, loss of 18q was corre-
lated with gain of 20q [14]. In colorectal cancer, this
combination of events is associated with a higher grade
of dysplasia [14]. The association of loss of 18q22.1
with survival suggests the possibility that the abnor-
malities of the gene present on chromosome 18q22.1
or nearby may contribute to tumour growth.
Here we report a genome-wide microarray CGH
study of gastric cancer and the correlation with clini-
copathological characteristics and survival. Microarray
CGH has revealed several chromosomal regions that
have not described before in gastric cancer at this
frequency and resolution, such as amplification of
7q21–q22 and 12q14.1–q21.1, as well gains at 1q32.3,
7p11.2, and losses at 13q13.1.
In particular gain of 1q is associated with a poor
prognosis and loss of 18q with poor survival. This sug-
gests that at 1q32.3 oncogene(s) and 18q22.1 tumour
supressor gene(s) are located that may determine ag-
gressive tumour behaviour and poor clinical outcome.
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